[A history and review of cholesterol ester transfer protein inhibitors and their contribution to the understanding of the physiology and pathophysiology of high density lipoprotein] [0.03%]
[胆固醇酯转移蛋白抑制剂的研究历史及其对高密度脂蛋白生理学和病理生理学理解的贡献]
Pablo Corral,Laura Schreier
Pablo Corral
There is irrefutable evidence that statins reduce the risk of cardiovascular events in a magnitude proportional to the intensity of the decrease in cholesterol transport by the low density lipoproteins. Despite this great advance there is s...
Statins and percutaneous coronary intervention: a complementary synergy [0.03%]
他汀与经皮冠状动脉介入治疗：互补的协同作用
Darío Echeverri,Jaime Cabrales
Darío Echeverri
The inclusion of statins and stents in coronary disease management during the 1980s has marked a dramatic change in the natural history of the disease. Separately, each of these therapies have progressed rapidly and have achieved a prime po...
[Prevention of cardiovascular diseases needs prevention for arteriosclerosis development and its risk factors] [0.03%]
心血管病防制重在动脉粥样硬化及其危险因素的防治
Fernando Civeira
Fernando Civeira
[Expert consensus on the detection and clinical management of familial hypercholesterolemia] [0.03%]
[家族性高胆固醇血症的筛查与临床管理专家共识]
Lluís Masana,Fernando Civeira,Juan Pedro-Botet et al.
Lluís Masana et al.
Familial hypercholesterolemia (FH) is one of the most common and severe genetic diseases, causing disabilities and premature death to those who suffer it. Lipid-lowering therapy substantially improves the prognosis of FH patients and, there...
[Achievement of low-density lipoprotein cholesterol therapeutic goal in lipid and vascular risk units of the Spanish Arteriosclerosis Society] [0.03%]
西班牙动脉硬化学会脂质和血管风险单位中的低密度脂蛋白胆固醇治疗目标达成状况
Juan Pedro-Botet,José M Mostaza,Xavier Pintó et al.
Juan Pedro-Botet et al.
Objective: To evaluate low-density lipoprotein-cholesterol (LDLc) goal achievement among dyslipidemic patients treated in lipid and vascular risk units of the Spanish Society of Arteriosclerosis (SEA). The LDLc goal was b...
[Alterations in the protein content and dysfunction of high-density lipoproteins from hyperhomocysteinemic mice] [0.03%]
同型半胱氨酸血症小鼠HDL蛋白质组的改变及HDL功能异常
Josep Julve,Teresa Laura Errico,Xiangyu Chen et al.
Josep Julve et al.
Aim: The aim of this study was to evaluate the proteic changes in high-density lipoproteins (HDL) induced by methionine-induced hyperhomocysteinemia in mice and its relationship with two of their main antiatherogenic prop...
[Anthropometric measures of central abdominal fat and discriminant capacity for metabolic syndrome in a Spanish population] [0.03%]
西班牙人群中中央型腹脂肪的体质测量学指标及其鉴别代谢综合征的价值
Diego Bellido,Martín López de la Torre,José Carreira et al.
Diego Bellido et al.
Introduction: The metabolic syndrome (MS) carries an increased risk of cardiovascular disease and diabetes mellitus. Insulin resistance is probably the mechanism underlying the changes detected in lipid and carbohydrate m...
[Psychosis, cardiovascular risk and associated mortality: are we on the right track?] [0.03%]
[精神病、心血管风险和相关死亡率：我们是否走在正确的道路上？]
Miguel Castillo Sánchez,Mireia Fàbregas Escurriola,Daniel Bergè Baquero et al.
Miguel Castillo Sánchez et al.
Patients with psychotic disorders have a higher risk of early mortality. In addition to unnatural causes (accidents, suicide), death due to cardiovascular (CV) reasons is two to four times more prevalent in these patients than in the genera...
Ovidio Muñiz Grijalvo,Jose Villar Ortiz
Ovidio Muñiz Grijalvo
Statins are the current basis of lipid-lowering therapy, despite which may have limitations on efficacy and safety. In high risk patients who do not achieve current lipid goals, in those intolerant to statins or those with atherogenic dysli...
T Arrobas-Velilla,R Mondéjar-García,J A Gómez-Gerique et al.
T Arrobas-Velilla et al.
Hyperglycerolemia is a very rare genetic disorder caused by glycerol kinase deficiency. Although usually is presented unexpectedly in routine checks, there are severe forms, especially in children. In general, glycerol and glycerol kinase a...